Now Approved banner

KALYDECO® (ivacaftor) is indicated to treat patients age 4 months and older with one of 38 CFTR mutations1

 

KALYDECO is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator indicated for the treatment of cystic fibrosis (CF) in patients age 4 months and older who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data.